¹H NMR-based serum metabolic profiling in compensated and decompensated cirrhosis.

Aim: To study the metabolic profiling of serum samples from compensated and decompensated cirrhosis patients.

Methods: A pilot metabolic profiling study was conducted using three groups: compensated cirrhosis patients (n = 30), decompensated cirrhosis patients (n = 30) and healthy controls (n = 30). A ¹H nuclear magnetic resonance (NMR)-based metabonomics approach was used to obtain the serum metabolic profiles of the samples.

How does short-term low-dose simvastatin influence serum prohepcidin levels in patients with end-stage renal disease? A pilot study.

Anemia is a common clinical problem in end-stage renal disease (ESRD). Despite adequate erythropoiesis-stimulating agent (ESA) supplementation, some ESRD patients still have suboptimal hemoglobin levels, and iron deficiency and inflammation are recognized as the two most common causes. Hepcidin, a newly discovered key regulator of iron homeostasis, is found to be accumulated in ESRD.